The clinical-stage generative AI drug discovery company recorded a net profit of $35.54 million and an adjusted net profit of $51.23 million, with positive operating cash flow, in its first interim report since listing on the Hong Kong Stock Exchange at the end of 2025. The results, released August 26, 2026, mark the first time an AI-driven drug discovery company of Insilico’s profile has reported full-period profitability. The figure worth scrutinizing is not the margin but the revenue mix…